To Get Full Access :

Ngenla

Ngenla is an injection of long-acting growth hormone, administered once a week, for children 3 years and older with growth hormone deficiency. It helps support normal growth using a prefilled pen system.

The information outlined in the molecule details section below would help you plan aBLA development early to enable a streamlined and competitive biosimilar strategy.

Molecule Details :

  • Molecule Name :

    Somatrogon-Ghla
  • Innovator :

    OPKO/PFIZER
  • Approval Date :

    27-Jun-23
  • Data Exclusivity Expiry :

    27-Jun-27
  • Market Exclusivity Expiry :

    27-Jun-35
  • Dosage Form :

    Prefilled Injection
  • Strength :

    24mg and 60mg
  • Therapeutic Category :

    Hormonal Therapy
  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    110
  • 2026 :

    196
  • 2027 :

    255
  • 2028 :

    331
  • 2029 :

    399
  • 2030 :

    457
  • 2031 :

    508
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?